Huawei held its MEA Tech Innovation Talks conference in Dubai on 23 October 2026, bringing together researchers and technology and healthcare experts to focus on wearable-based cardiovascular monitoring and related health research.
The event took place at Grand Plaza Movenpick and followed Huawei’s debut of the HUAWEI WATCH D3 at ISH-ECS 2026. Huawei said the watch was unveiled alongside discussions intended to support developments in blood pressure monitoring and early risk identification for conditions including diabetes.
ISH-ECS 2026, described by Huawei as an annual gathering dedicated to hypertension, runs in Dubai from 22 to 25 October 2026 and brings together organisations and experts to discuss research and developments in hypertension prevention and management. Huawei stated that the MEA Tech Innovation Talks conference was held on the sidelines of ISH-ECS 2026.
Wearables, cardiovascular risk and diabetes screening
Huawei said that international experts presented findings from research using HUAWEI WATCH D Series wearable blood pressure monitoring devices. The presentations, according to the company, explored how wearable technology could help support blood pressure monitoring and management.
Huawei’s conference agenda, as described in the release, highlighted three areas of progress: blood pressure monitoring, coronary heart disease risk research, and diabetes risk assessment. The release also said the discussions examined how wearable technology could contribute to preventive and personalised healthcare.
Professor Jiguang Wang, Professor of Cardiovascular Medicine at the Shanghai Institute of Hypertension, commented that the HUAWEI WATCH D3 could point to a future where blood pressure monitoring is integrated into everyday life. He said innovations including “Minimally Disruptive ABPM and environmental monitoring reminder by Huawei Watch D3” may help shape how blood pressure management is automated and embedded through wearable devices.
Professor George Stergiou, President of the International Society of Hypertension, described the HUAWEI WATCH D3 as a “novel, reliable wearable device” that provides insights into blood pressure profiles and patterns. The release states he also noted that the European Society of Hypertension and the International Society of Hypertension encourage the clinical use of validated wrist-cuff blood pressure monitors, and called for additional research into implementation in clinical practice.
Other speakers cited in the release included Professor Datin Yook-Chin Chia, who said reducing disruption and the number of required measurements could make comprehensive ABPM more practical for patients, and Professor Maryam Al Saeed of Mohammed Bin Rashid University of Medicine and Health Sciences, who said a collaboration between Dubai Health and Huawei is evaluating non-invasive wearable technology for earlier diabetes risk. The release attributes to her an emphasis on using real-world health data to support proactive prevention.
Research investment and a hypertension innovation fund
In its announcement, Huawei said it invested USD 28.62 billion in R&D in 2025, which it described as 21.8% of annual revenue. The company also said it established the Wearable Blood Pressure Technology Innovation Fund in collaboration with the International Society of Hypertension to support further research into hypertension.
Technologies showcased alongside wearables
Alongside the healthcare-focused sessions, the release said Huawei presented smartphone-related innovation during the conference, including foldable smartphone and camera technology. Edwin You, Chief Technology Officer at Huawei, also spoke about Tau Law, described as a chip-design approach intended to reduce signal propagation delays and shift emphasis away from shrinking transistor dimensions.
